BYDUREON Receives Marketing Authorization in Europe (LLY) (ALKS) (AMLN)

Eli Lilly and Company (NYSE: LLY), together with Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes, Inc. (Nasdaq: ALKS), report that the European Commission has granted marketing authorization to BYDUREON™ (exenatide 2 mg powder and solvent for prolonged release suspension for injection).

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
• Roots Corporation to go private in C$4.10-per-share deal with Marquee Brands
• Getty Realty discloses separation terms for departing accounting officer